Macarena Silva1,2,3, Carmen G Montes4, Andrea Canals5,6, Maria J Mackenna4,5,6,7, Marcelo Wolff1,2,3. 1. Arriarán Foundation, Santiago, Chile. 2. Department of Infectious Diseases, San Borja-Arriarán Hospital, Santiago, Chile. 3. School of Medicine, University of Chile, Santiago, Chile. 4. Nutrition and Food, Mention in Human Nutrition, Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile. 5. Biostatistics, Public Health School, University of Chile, Santiago, Chile. 6. Academic Direction, Santa Maria Clinic, Santiago, Chile. 7. Nutrition Department, Las Condes Clinic, Santiago, Chile.
Abstract
INTRODUCTION: It has been estimated that between 15% and 18% of patients who start antiretroviral therapy (ART) do not achieve a successful immune recovery despite complete virological suppression. In the literature this phenomenom is known as poor immune recovery or immunovirological discordance (IVD). Zinc has an immunomodulatory role associated with T lymphocytes and its supplementation could enhance immune recovery. OBJECTIVE: To determine if zinc supplementation on IVD patients prevents immune failure after 12 months of supplementation. Secondary objectives were to determine serum zinc levels in HIV patients with and without IVD and the frequency of hypozincemia in discordant patients. METHOD: We reviewed the historical record of patients under care at Arriarán Foundation. Following inclusion criteria were defined: 1) age ≥ 18 years, 2) standard ART (three effective drugs) for at least 18 months, 3) virologically suppressed for 12 months, 3) persistence of CD4 count ≤200 cells/mm3 and/or increase ≤ 80 cells/mm3 after one year of viral undetectability. A control group was assigned paired 1:1 by sex, age (± 2 years) that did achieved an increase of CD4>; 350 cells/ mm3. In both groups plasma zinc levels were determined. In a later phase, patients with IVD were randomized to receive zinc (15 mg daily) versus placebo. Patients were followed for 12 months with CD4 count, viral load and zinc levels determinations every 4-6 months. RESULTS: A total of 80 patients, 40 patients with IVD criteria and 40 controls were included. 92.5% were men, and age average was 47.5 years. The median baseline CD4 was 189 cells/mm3 (71-258) in the cases vs. 552.5 cells/ mm3 (317-400) in the control group with a median increase at the end of the study of 39 cell/mm3 and 19 cell/mm3 respectively. There was no difference in baseline plasma zinc levels between both groups (81.7 + 18.1 in cases versus 86.2 + 11.0 in controls). In the 40 patients with IVD, the median absolute increase in CD4 after annual zinc supplementation was 31.5 cells/mm3 in the treated group versus 50 cells/mm3 in the placebo group, this difference being statistically not significant (p = 0.382). CONCLUSIONS:Patients with IVD have plasma zinc levels similar to those who achieve adequate immune recovery. Zinc supplementation in IVD patients showed a statistically non-significant difference in in CD4 levels between cases and controls. The results warrant a comparative study with a larger number of patients.
RCT Entities:
INTRODUCTION: It has been estimated that between 15% and 18% of patients who start antiretroviral therapy (ART) do not achieve a successful immune recovery despite complete virological suppression. In the literature this phenomenom is known as poor immune recovery or immunovirological discordance (IVD). Zinc has an immunomodulatory role associated with T lymphocytes and its supplementation could enhance immune recovery. OBJECTIVE: To determine if zinc supplementation on IVDpatients prevents immune failure after 12 months of supplementation. Secondary objectives were to determine serum zinc levels in HIVpatients with and without IVD and the frequency of hypozincemia in discordant patients. METHOD: We reviewed the historical record of patients under care at Arriarán Foundation. Following inclusion criteria were defined: 1) age ≥ 18 years, 2) standard ART (three effective drugs) for at least 18 months, 3) virologically suppressed for 12 months, 3) persistence of CD4 count ≤200 cells/mm3 and/or increase ≤ 80 cells/mm3 after one year of viral undetectability. A control group was assigned paired 1:1 by sex, age (± 2 years) that did achieved an increase of CD4> 350 cells/ mm3. In both groups plasma zinc levels were determined. In a later phase, patients with IVD were randomized to receive zinc (15 mg daily) versus placebo. Patients were followed for 12 months with CD4 count, viral load and zinc levels determinations every 4-6 months. RESULTS: A total of 80 patients, 40 patients with IVD criteria and 40 controls were included. 92.5% were men, and age average was 47.5 years. The median baseline CD4 was 189 cells/mm3 (71-258) in the cases vs. 552.5 cells/ mm3 (317-400) in the control group with a median increase at the end of the study of 39 cell/mm3 and 19 cell/mm3 respectively. There was no difference in baseline plasma zinc levels between both groups (81.7 + 18.1 in cases versus 86.2 + 11.0 in controls). In the 40 patients with IVD, the median absolute increase in CD4 after annual zinc supplementation was 31.5 cells/mm3 in the treated group versus 50 cells/mm3 in the placebo group, this difference being statistically not significant (p = 0.382). CONCLUSIONS:Patients with IVD have plasma zinc levels similar to those who achieve adequate immune recovery. Zinc supplementation in IVDpatients showed a statistically non-significant difference in in CD4 levels between cases and controls. The results warrant a comparative study with a larger number of patients.
Authors: A Zoufaly; M an der Heiden; C Kollan; J R Bogner; G Fätkenheuer; J C Wasmuth; M Stoll; O Hamouda; J van Lunzen Journal: J Infect Dis Date: 2010-12-08 Impact factor: 5.226
Authors: Raziya Bobat; Hoosen Coovadia; Cindy Stephen; Kimesh L Naidoo; Neil McKerrow; Robert E Black; William J Moss Journal: Lancet Date: 2005-11-26 Impact factor: 79.321
Authors: Christine M McDonald; Karim P Manji; Rodrick Kisenge; Said Aboud; Donna Spiegelman; Wafaie W Fawzi; Christopher P Duggan Journal: J Nutr Date: 2015-07-22 Impact factor: 4.798
Authors: Suely H Tuboi; Martin W G Brinkhof; Matthias Egger; Roslyn A Stone; Paula Braitstein; Denis Nash; Eduardo Sprinz; François Dabis; Lee H Harrison; Mauro Schechter Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Frederik N Engsig; Robert Zangerle; Olga Katsarou; Francois Dabis; Peter Reiss; John Gill; Kholoud Porter; Caroline Sabin; Andrew Riordan; Gerd Fätkenheuer; Félix Gutiérrez; Francois Raffi; Ole Kirk; Murielle Mary-Krause; Christoph Stephan; Patricia Garcia de Olalla; Jodie Guest; Hasina Samji; Antonella Castagna; Antonella d'Arminio Monforte; Adriane Skaletz-Rorowski; Jose Ramos; Giuseppe Lapadula; Cristina Mussini; Lluís Force; Laurence Meyer; Fiona Lampe; Faroudy Boufassa; Heiner C Bucher; Stéphane De Wit; Greer A Burkholder; Ramon Teira; Amy C Justice; Tim R Sterling; Heidi M Crane; Jan Gerstoft; Jesper Grarup; Margaret May; Geneviève Chêne; Suzanne M Ingle; Jonathan Sterne; Niels Obel Journal: Clin Infect Dis Date: 2014-01-22 Impact factor: 9.079
Authors: Alexander Zoufaly; Alessandro Cozzi-Lepri; Joanne Reekie; Ole Kirk; Jens Lundgren; Peter Reiss; Djordje Jevtovic; Ladislav Machala; Robert Zangerle; Amanda Mocroft; Jan Van Lunzen Journal: PLoS One Date: 2014-01-31 Impact factor: 3.240